Brief: Shield Therapeutics Says FDA Grants Additional Exclusivity For ACCRUFeR
09/02/2026 07:27
Feb 9 (Reuters) - Shield Therapeutics PLC STXS.L: SHIELD THERAPEUTICS - FDA GRANTS ADDITIONAL EXCLUSIVITY FOR ACCRUFER SHIELD THERAPEUTICS : EXCLUSIVITY REMAINS IN PLACE UNTIL 19 DEC 2028 IN ADDITION TO ACCRUFER/FERACCRU PATENT COVERAGE VALID UNTIL MID-2030S Source text: ID:nRSI2151Sa Further company coverage: STXS.L (((( Reuters.Briefs@thomsonreuters.com ;));))
Recent news on Shield Therapeutics
See all newsBrief: Shield Therapeutics To Assume Full Commercial Control Of ACCRUFeR In US
Shield Therapeutics - Shield assumes full control of ACCRUFeR® in the US
Shield Therapeutics - Interim results for the six months ended 30 Jun 26
Brief: Shield Therapeutics Says On Track For Profitability In 2026; Appoints Michael Jensen As CFO
Shield Therapeutics - Q2 and H1 2026 Trading Update